A benefit-risk assessment of dapoxetine in the treatment of premature ejaculation

Drug Safety

Volumn 35, Issue 5, 2012, Pages 359-372

  Hutchinson, Kate ^a   Cruickshank, Kelly ^a   Wylie, Kevan ^a,b,c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b Porterbrook Clinic   (United Kingdom)

^c SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

Author keywords

Benefit risk assessment; Clomipramine; Dapoxetine; Erectile dysfunction; Fluoxetine; Local anaesthetics; Paroxetine; Premature ejaculation; Serotonin uptake inhibitors; Sertraline; Tramadol; Type 5 cyclic nucleotide phosphodiesterase inhibitors.

Indexed keywords

CITALOPRAM; CLOMIPRAMINE; DAPOXETINE; FLUOXETINE; FLUVOXAMINE; LIDOCAINE; LOCAL ANESTHETIC AGENT; NATURAL PRODUCT; NEFAZODONE; PAROXETINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PRILOCAINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SEVERANCE SECRET; SILDENAFIL; TRAMADOL; UNCLASSIFIED DRUG;

AGITATION; ANORGASMIA; BEHAVIOR THERAPY; BURNING SENSATION; CONFUSION; CONSCIOUSNESS DISORDER; CONSTIPATION; CONVULSION; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; ECG ABNORMALITY; EJACULATION; ERECTILE DYSFUNCTION; FLUSHING; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HEART BLOCK; HUMAN; INSOMNIA; INTAVAGINAL EJACULATORY LATENCY TIME; LATENT PERIOD; LIBIDO DISORDER; MEDICAL LITERATURE; MULTICENTER STUDY (TOPIC); NAUSEA; OBSESSIVE COMPULSIVE DISORDER; OFF LABEL DRUG USE; PAIN; PARESTHESIA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL (TOPIC); PREMATURE EJACULATION; PRIORITY JOURNAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEX THERAPY; SEXUAL INTERCOURSE; SEXUAL SATISFACTION; SIDE EFFECT; SOMNOLENCE; SQUEEZE TECHNIQUE; SYNCOPE; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TOPICAL TREATMENT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VOMITING; XEROSTOMIA;

EID: 84859822861     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11598150-000000000-00000     Document Type: Review

References (44)

1. Linton K, Wylie K. Recent advantages in the treatment of premature ejaculation. Drug Des Devel Ther 2010; 4: 1-6
2. Buvat J, Tesfaye F, Rothman M, et al. Dapoxetine for the treatment of premature ejaculation: results from a randomised, double-blind, placebo-controlled phase 3 trial in 22 countries. Eur Urol 2009; 55: 957-68
3. Kaufman JM, Rosen RC, Mudumbi RV, et al. Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU Int 2008; 103: 651-8
4. Althof SE, Abdo CH, Dean J, et al. International Society for Sexual Medicines guidelines for the diagnosis and treatment of premature ejaculation. J Sex Med 2010; 7 (9): 2947-69
5. Ralph D, Wylie K. Ejaculatory disorders and sexual function. BJU Int 2005; 95: 1181-6
6. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 2000
7. Owen R. Dapoxetine: a novel treatment for premature ejaculation. Drugs Today 2009; 45 (9): 669-78
8. Giuliano F, Clement P. Serotonin and premature ejaculation: from physiology to patient management. Eur Urol 2006; 50: 454-66
9. Shabsigh R, Patrick DL, Rowland DL, et al. Perceived control over ejaculation is central to treatment benefit in men with premature ejaculation: results from phase III trials with dapoxetine. BJU International 2008; 102: 824-8
10. Perelman M. A new combunation treatment for premature ejaculation: a sex therapists perspective. J Sex Med 2006; 3: 1004-12
11. Gurkan L, Oommen M, Hellstrom W. Premature ejaculation: current and future treatments. Asian J Androl 2008; 10 (1): 102-9
12. Richardson D, Goldmeier D, Green J, et al. Recommendations for the management of premature ejaculation: BASHH special interest group for sexual dysfunction. Int J STD AIDS 2006; 17: 1-6
13. Waldinger MD, Zwinderman AH, Schweitzer DH, et al. Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res 2004; 16 (4): 369-81
14. Kendici M, Salem E, Hellstrom W. Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation. Ther Clin Risk Man 2007; 3: 277-89
15. Modi NB, Dresser MJ, Simon M, et al. Single- and multipledose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol 2006; 46: 301-9
16. Andersson K, Muhall J, Wyllie M. Pharmacokinetic and pharmacodynamic features of dapoxetine, a novel ondemand treatment of premature ejaculation. BJU Int 2006; 97: 311-5
17. McMahon C, Kim SW, Park NC, et al. Treatment of premature ejaculation in the Asia-Pacific region: results from a phase III double-blind, parallel-group study of dapoxetine. J Sex Med 2010; 7: 256-68
18. Pryor JL, Althof SE, Steidle C, et al. Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet 2006; 368: 929-37
19. Safarinejad M. Comparison of dapoxetine versus paroxetine in patients with premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomised study. Clin Neuropharmacol 2006; 29: 243-52
20. Safarinejad M. Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebocontrolled, fixed-dose, randomised study. Neuropsychopharmacology 2008; 33: 1259-65
21. Rosen RC, Riley A,Wagner G, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.Urology 1997; 49 (6): 822-30
22. Modi N. Single and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation. J Clin Pharmacol 2006; 46: 301-9
23. Kowey PR, Mudumbi RV, Aquilina JW, et al. Cardiovascular safety profile of dapoxetine during the premarketing evaluation. Drugs R D 2011; 11 (1): 1-11
24. McMahonCG,McMahon CN, LeowLJ, et al. Efficacy of type- 5 phosodiesterase inhibitors in the drug treatment of premature ejaculation: a systemic review. BJU Int 2006; 98: 259-72
25. McMahon C. Dapoxetine for premature ejaculation. Expert Opin Pharmacother 2010; 11: 1741-52
26. Waldinger M, Zwinderman A, Oliver B. Antidepressants and ejaculation: a double-blind, randomised, placebocontrolled, fixed-dose study with paroxetine, sertraline and nefazodone. J Clin Psychopharmacol 2001; 21: 293-7
27. Waldinger M, Zwinderman A, Olivier B. On-demand treatment of premature ejaculation with clomipramine and paroxetine: a randomised, double-blind, fixed-dose study with stopwatch assessment. Eur Urol 2004; 46: 510-6
28. Morales A, Barada J, Wyllie M. A review of the current status of topical treatments for premature ejaculation. BJU Int 2007; 100: 493-501
29. Schapiro B. Premature ejaculation, a review of 1130 cases. J Urol 1943; 50: 374-9
30. Choi HK, Hung GW, Moon KH, et al. Clinical study of SS-cream in patients with lifelong premature ejaculation. Urology 2000; 55: 257-61
31. Dinsmore WW, Hackett G, Goldmeier D, et al. Topical eutectic mixture for premature ejaculation (TEMPE): a novel, aerosol-delivery form of lidocaine-prilocaine for treating premature ejaculation. BJU Int 2006; 99: 369-75
32. Kim S, Seo K. Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo-controlled study. J Urol 1998; 159: 425-7
33. Wang WF, Wang Y, Minhas S, et al. Can sildenafil treat primary premature ejaculation? A prospective clinical study. Int J Urol 2007; 14: 331-5
34. Safarinejad M, Hosseini S. Safety and efficacy of tramadol in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomised study. J Clin Psychopharmacol 2006; 26 (1): 27-31
35. Salem EA, Wilson SK, Bissada NK, et al. Tramadol HCl has promise in on-demand use to treat premature ejaculation. J Sex Med 2008; 5: 188-93
36. Joint Formulary Committee. British National Formulary. 60th ed. London: British Medical Association and Royal Pharmaceutical Society, 2010
37. Mohammed M. Clomipramine as daily dose in the treatment of patients with premature ejaculation: prospective placebocontrolled study. Basrah J Surg 2007; 13: 75-9
38. Waldinger M. Premature ejaculation: different pathophysiologies and etiologies determine its treatment. J S Marital Ther 2008; 34: 1-13
39. Atan A, Basar MM, Tuncel A, et al. Comparison of efficacy of sildenafil-only, sildenafil plus topical EMLA cream, and topical EMLA-cream-only in the treatment of premature ejaculation. Urology 2006; 67: 388-91
40. Semans JH. Premature ejaculation: a new approach. South Med J 1956; 49 (4): 353-8
41. Jannini EA, McCabe MP, Salonia A, et al. Organic vs. psychogenic? The Manichean diagnosis in sexual medicine. J Sex Med 2010; 7: 1726-33
42. Hoy S, Scott L. Dapoxetine in premature ejaculation. Drugs 2010; 1433-43
43. Murat Basar M, Atan A, Yildiz M, et al. Comparison of sertraline to fluoxetine in regard to their efficacy and side effects in the treatment of premature ejaculation. Arch Esp Urol 1999; 52: 1008-11
44. Richardson D, Goldmeier D. Pharmacological treatment for premature ejaculation. Int J STD AIDS 2005; 16: 709-11